Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and President of MSD China, announced this week a significant adjustment to the company’s organizational structure. A new entrepreneur business unit will be established, focusing on the US giant’s mature products in the fields of infection, oncology, and diabetes, many of which are covered by volume-based procurement.
New Department and Strategy
The newly created department, effectively succeeding the diabetes business unit (DBU), aims to create a synergistic product line through data insights, hospital and retail channel strategies, and value-driven customer interactions. This approach is designed to promote the sustainable growth of mature products.
Leadership Appointments
On the same day, three major leadership appointments were announced, effective from April 1:
- Fan Bairui will lead the oncology division, continuing to oversee MSD’s innovative oncology drugs.
- Wang Xiaoxiang will head the innovative drug division, focusing on the continuous growth of new product launches and strategic drugs.
- Xu Peng will continue to lead the vaccine division, which includes products such as cervical cancer vaccines.-Fineline Info & Tech
Leave a Reply